Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Valganciclovir Hydrochloride

FDA-approved product (tablet, oral), marketed as Valcyte, Valganciclovir Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Valganciclovir Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AIDS
  • Cytomegalovirus Retinitis
  • Retinitis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB14

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Valganciclovir Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Valganciclovir Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

    NCT01165580 · start 2011-05

    Registered record
    Registry ID
    NCT01165580
    Conditions
    Cytomegalovirus Infections, Heart Transplantation
    Interventions
    valganciclovir [Valcyte]
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2013-09
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections, Heart Transplantation
    Interventionvalganciclovir [Valcyte]
    PhasePhase 1
    Registry statusCompleted

  • Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

    NCT01199562 · start 2010-12

    Registered record
    Registry ID
    NCT01199562
    Conditions
    Hematopoietic/Lymphoid Cancer; Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13; q22); Adult Acute Myeloid Leukemia With t(15; 17)(q22; q12); Adult Acute Myeloid Leukemia With t(16; 16)(p13; q22); Adult Acute Myeloid Leukemia With t(8; 21)(q22; q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adul
    Interventions
    infection prophylaxis and management; laboratory biomarker analysis; flow cytometry; DNA analysis; RNA analysis; management of therapy complications; ganciclovir; valganciclovir; foscarnet sodium; antiviral therapy; polymerase chain reaction; protein expression analysis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2010-12
    Completion
    2026-12-01
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic/Lymphoid Cancer; Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission +27 more
    Interventioninfection prophylaxis and management; laboratory biomarker analysis; flow cytometry; DNA analysis +8 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation

    NCT01185223 · start 2010-09

    Registered record
    Registry ID
    NCT01185223
    Conditions
    Allogeneic Stem Cell Transplantation
    Interventions
    Valganciclovir; Ganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-09
    Completion
    Not recorded
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogeneic Stem Cell Transplantation
    InterventionValganciclovir; Ganciclovir
    PhasePhase 3
    Registry statusTerminated

  • An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients

    NCT02062294 · start 2010-07-31

    Registered record
    Registry ID
    NCT02062294
    Conditions
    Cytomegalovirus Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-07-31
    Completion
    2011-09-30
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

    NCT00992732 · start 2010-05

    Registered record
    Registry ID
    NCT00992732
    Conditions
    Lymphoid Malignancies; Lymphoproliferative Disorders
    Interventions
    HQK-1004; Valganciclovir (may substitute with ganciclovir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-05
    Completion
    Not recorded
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoid Malignancies; Lymphoproliferative Disorders
    InterventionHQK-1004; Valganciclovir (may substitute with ganciclovir)
    PhasePhase 2
    Registry statusTerminated

  • IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients

    NCT00294515 · start 2006-03-31

    Registered record
    Registry ID
    NCT00294515
    Conditions
    Cytomegalovirus Infections
    Interventions
    Valganciclovir; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03-31
    Completion
    2009-08-31
    Enrolment
    326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections
    InterventionValganciclovir; Valganciclovir
    PhasePhase 3
    Registry statusCompleted

  • Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

    NCT00217503 · start 2005-07

    Registered record
    Registry ID
    NCT00217503
    Conditions
    Lymphoma
    Interventions
    bevacizumab; filgrastim; pegfilgrastim; bortezomib; cyclophosphamide; doxorubicin hydrochloride; etoposide; ganciclovir; valganciclovir; zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-07
    Completion
    2007-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionbevacizumab; filgrastim; pegfilgrastim; bortezomib +6 more
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of Mmf and Valganciclovir

    NCT00189150 · start 2005-04

    Registered record
    Registry ID
    NCT00189150
    Conditions
    Kidney Transplant Recipient; Heart Transplant Recipient
    Interventions
    Mycophenolate mofetil; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Recipient; Heart Transplant Recipient
    InterventionMycophenolate mofetil; Valganciclovir
    PhasePhase 4
    Registry statusCompleted

  • Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

    NCT00241345 · start 2004-06

    Registered record
    Registry ID
    NCT00241345
    Conditions
    Cytomegalovirus Infections
    Interventions
    Valganciclovir; Ganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2004-06
    Completion
    2007-12
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections
    InterventionValganciclovir; Ganciclovir
    PhasePhase 3
    Registry statusTerminated

  • Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

    NCT00141037 · start 2004-03

    Registered record
    Registry ID
    NCT00141037
    Conditions
    Kidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation; Renal Transplant
    Interventions
    Daclizumab; Mycophenolate mofetil (MMF); Prednisone; Tacrolimus; Ganciclovir; Valganciclovir; Trimethoprim and sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-03
    Completion
    2010-11
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation +1 more
    InterventionDaclizumab; Mycophenolate mofetil (MMF); Prednisone; Tacrolimus +3 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients

    NCT00225394 · start 2003-10

    Registered record
    Registry ID
    NCT00225394
    Conditions
    CMV Disease; Viral Resistance; Rejection; Death
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-10
    Completion
    2006-07
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Disease; Viral Resistance; Rejection; Death
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Oral Valganciclovir Versus Valacyclovir

    NCT00562770 · start 2003-09

    Registered record
    Registry ID
    NCT00562770
    Conditions
    Chronic Lymphocytic Leukemia; Leukemia
    Interventions
    Valganciclovir; Valacyclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-09
    Completion
    2006-07
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Leukemia
    InterventionValganciclovir; Valacyclovir
    PhasePhase 2
    Registry statusCompleted

  • Study of Prophylactic Vs Preemptive Valganciclovir

    NCT00374686 · start 2003-03

    Registered record
    Registry ID
    NCT00374686
    Conditions
    Cytomegalovirus Infection
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-03
    Completion
    2005-09
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infection
    InterventionValganciclovir
    PhaseNot applicable
    Registry statusCompleted

  • Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients

    NCT00198224 · start 2003-01

    Registered record
    Registry ID
    NCT00198224
    Conditions
    Renal Failure
    Interventions
    phlebotomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-01
    Completion
    2005-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Failure
    Interventionphlebotomy
    PhaseNot applicable
    Registry statusCompleted

  • Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

    NCT00034385 · start 2002-04-24

    Registered record
    Registry ID
    NCT00034385
    Conditions
    Kidney Trasplant
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-04-24
    Completion
    2009-10-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Trasplant
    InterventionValganciclovir
    PhasePhase 4
    Registry statusCompleted